LABORATORY CORPORATION OF AMERICA HOLDINGS Laboratory Corporation of America Holdings Stock
Equities
LH
US50540R4092
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 203.3 USD | -1.17% |
|
-3.24% | -10.55% |
| Apr. 11 | Labcorp Keeps Quarterly Dividend at $0.72 Per Share, Payable June 12 to Stockholders of Record May 28 | MT |
| Apr. 11 | Labcorp Declares Quarterly Dividend, Payable on June 12, 2024 | CI |
Financials (USD)
| Sales 2024 * | 12.76B | Sales 2025 * | 13.31B | Capitalization | 17.31B |
|---|---|---|---|---|---|
| Net income 2024 * | 994M | Net income 2025 * | 1.11B | EV / Sales 2024 * | 1.7 x |
| Net Debt 2024 * | 4.35B | Net Debt 2025 * | 3.85B | EV / Sales 2025 * | 1.59 x |
| P/E ratio 2024 * |
17.4
x | P/E ratio 2025 * |
15.5
x | Employees | 61,975 |
| Yield 2024 * |
1.44% | Yield 2025 * |
1.49% | Free-Float | 99.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Laboratory Corporation of America Holdings
More recommendations
More press releases
More news
| 1 day | -0.37% | ||
| 1 week | -2.62% | ||
| Current month | -5.83% | ||
| 1 month | -1.57% | ||
| 3 months | -7.94% | ||
| 6 months | +2.07% | ||
| Current year | -9.49% |
1 week
204.01
212.69
1 month
204.01218.67
Current year
204.01234.09
1 year
195.01243.30
3 years
195.01317.17
5 years
98.02317.17
10 years
95.12317.17
| Managers | Title | Age | Since |
|---|---|---|---|
Adam Schechter
CEO | Chief Executive Officer | 59 | 13-03-31 |
Glenn Eisenberg
DFI | Director of Finance/CFO | 62 | 14-06-15 |
| Compliance Officer | 65 | 19-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Williams
BRD | Director/Board Member | 75 | 07-05-15 |
Adam Schechter
CEO | Chief Executive Officer | 59 | 13-03-31 |
| Director/Board Member | 74 | 95-04-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.97% | 2 M€ | +7.50% | ||
| 1.95% | 8 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 203.3 | -1.17% | 669,066 |
| 24-04-12 | 205.7 | -0.37% | 717,036 |
| 24-04-11 | 206.5 | -0.32% | 861,295 |
| 24-04-10 | 207.2 | -1.37% | 901,940 |
| 24-04-09 | 210 | -0.03% | 714,111 |
Delayed Quote Nyse, April 12, 2024 at 04:00 pm EDT
More quotes
Laboratory Corporation of America Holdings is the No. 2 clinical laboratory in the United States. Net sales (including intragroup) break down by activity as follows:
- clinical laboratory services (63.9%): routine testing, patient diagnosis, disease monitoring and treatment, and other services;
- development and clinical trial services (36.1%): for pharmaceutical, biotechnology, medical device and diagnostic companies.
Net sales are distributed geographically as follows : North America (81.2%), Europe (12.7%) and other (6.1%).
Calendar
2024-04-24
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
205.7
USD
Average target price
244.1
USD
Spread / Average Target
+18.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.49% | 17.31B | |
| -13.07% | 86.52B | |
| +19.26% | 85.39B | |
| +13.03% | 29.95B | |
| -8.87% | 15.23B | |
| -6.78% | 14.27B | |
| +3.73% | 12.23B | |
| -29.82% | 11.68B | |
| +24.49% | 11.44B | |
| +50.81% | 11.41B |
- Stock Market
- Equities
- LH Stock
